Overview

Safety and Efficacy of Systemic Chemotherapy Plus PD-1 Inhibitor in Combination With Bevacizumab in Gastric Cancer With Peritoneal Metastasis

Status:
ENROLLING_BY_INVITATION

Trial end date:
2026-03-01

Target enrollment:

Participant gender:

Summary

It is an open label, phase II study involved receiving albumin-bound paclitaxel plus S-1 combined with sintilimab and bevacizumab in patients with gastric cancer peritoneal metastasis.

Phase:

PHASE2

Details

Lead Sponsor:

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Treatments:

Albumin-Bound Paclitaxel
Bevacizumab
S 1 (combination)
sintilimab